Measurement and Prediction of Timolol Diffusion with and Without Simulated Tear Flow Rowe T.E 1, Akande J.A 1A, Reed K. 2 A Ophthalmic Formulation Development,

Slides:



Advertisements
Similar presentations
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Advertisements

Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
Results and Discussion Continued By: Kristin Ackermann Amanda Rohs Blanca Skelding.
Pharmacokinetics of Drug Absorption
Dale P. Conner, Pharm.D. Division of Bioequivalence OGD, CDER, FDA
A Seminar on In vitro In vivo Correlation
Pharmacokinetics & Pharmacodynamics of Controlled Release Systems Presented By: Govardhan.P Dept. of pharmaceutics, University College of Pharmaceutical.
Bioavailability and Bioequivalence
Transdermal Drug Delivery – Assessment of in vitro skin permeation Shashank Jain.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Bioequivalence of Topical Drug Products
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.
Bepotastine Besilate Ophthalmic Solution 1.5% and Degree of Reduced Ocular Itching in a Conjunctival Allergen Challenge Test JI Williams 1, G Torkildsen.
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
OVERVIEW OF DACA BIOEQUIVALENCE REPORT EVALUATION Presented by Solomon Shiferaw 31Augst 2010.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
Rathapon Asasutjarit, Ph.D.
Week 6- Bioavailability and Bioequivalence
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
A New Approach to Determining Drug Schedules Helen Moore 1, Cherry Lei 2, and Nelson ‘Shasha’ Jumbe 1 1 Modeling & Simulation; 2 Non-clinical Biostatistics;
1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
SALIVARY, PROTEIN UNBOUND AND TOTAL PLASMA CONC OF RIFAMPICIN HADIJA H SEMVUA 11/12/2015KCRI_PhD SYMPOSIUM
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
The Role of Benzalkonium Chloride in the Occurrence of Punctate Keratitis: A Meta- Analysis of Randomized, Controlled Clinical Trials S Trocme, MD, 1 L-J.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
The Prophylactic Effectiveness of Two Fluoroquinolones on Staphylococcus aureus in Rabbit Eyes Balzli C, Caballero A, Tang A, Weeks A, O’Callaghan R University.
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Introduction What is a Biowaiver?
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Bioavailability and Bioequivalence L 10,11.  Bioavailability is a measurement of the rate and extent (amount) to which the active ingredient or active.
Exact PK Equivalence for a bridging study Steven Novick, Harry Yang (MedImmune) and Xiang Zhang (NC State) NCB, October 2015.
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Design of Sustained Release Dosage Forms
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
415 PHT Plasma Level – Time Curve
Comparison of AzaSite® and Azithromycin 1% for Bacterial Conjunctivitis Christopher Crean 1, Jason L. Vittitow 1, Richard C. Zink 1, Lori Richards 1, Rozemarijn.
Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.
Correlation Between the Transdermal Permeation of Ketoprofen and its Solubility in Mixtures of a pH 6.5 Phosphate Buffer and Various Solvents Ref.: Drug.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
In vitro - In vivo Correlation
Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate Ref.: European Journal of Pharmaceutics.
Definitions and Concepts
MULTIPLE DOSAGE REGIMEN
Drug Response Relationships
Inclusion Complexes of Piroxicam with B-Cyclodextrin Derivatives
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
FGF-2 DAPI DMEM IL-1 FGF-2 Actin DMEM IL-1 25 KDa 20 KDa
Biopharmaceutics of modified release drug products
Hashem Alsaab*, Rami M. alzhrani, Sai HS. Boddu
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
Applications of Pharmacokinetics
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Invest. Ophthalmol. Vis. Sci ;55(4): doi: /iovs Figure Legend:
Clinical Pharmacokinetics
“Normal Stomach” SGF to FaSSIF “Hypochlorhydric” SGF to FaSSIF
PITFALLS TO BEWARE IN IN-VITRO RELEASE STUDIES Presented by: Maneesha Pande Department of Chemical Engineering, Indian Institute of Technology Delhi.
Corneal Effects of 1.5% Levofloxacin Ophthalmic Solution (IQUIX®) in Humans Mark B. Abelson, MD1,2 Gail Torkildsen, MD2; Aron Shapiro2; Ingrid Lapsa2.
Selected Bioavailability and Pharmacokinetic Calculations
Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats  Sateesh Khandavilli, Ramesh Panchagnula 
Presentation transcript:

Measurement and Prediction of Timolol Diffusion with and Without Simulated Tear Flow Rowe T.E 1, Akande J.A 1A, Reed K. 2 A Ophthalmic Formulation Development, 1 Encompass Pharmaceutical Services, Norcross, GA; Rowe T.E 1, Akande J.A 1A, Reed K. 2 A Ophthalmic Formulation Development, 1 Encompass Pharmaceutical Services, Norcross, GA; 2 Ophthalmic Formulation Development, Encompass Pharmaceutical Services, Hawthorn Woods, IL. To correlate in vitro trans corneal diffusion of Timolol under static and simulated tear flow conditions to published animal pharmacokinetic data. Under simulated tear flow conditions: Relative AUC and total % Timolol (180 min) values correctly indicate that a large increase in aqueous humor concentrations should result when Timoptic XE ® is administered as indicated in the summary tables. In addition, the maximum rate of corneal diffusion appears to occur for a longer time for Timoptic XE ® than for the Timolol solution. This is in agreement with the later aqueous humor t max value given for Timoptic XE ® as compared to Timolol solution. Addicks J. Pharmaceutical research, Vol *Burgalassi et. al. J. Ocular Pharm. Therapeutics,Vol.16, No 6, pp Chiang C. J. Ocular Pharm. Therapeutics,Vol.12, No 4, pp Edman, P. Biopharmaceutics of Ocular Drug Delivery It is recognized that the topical delivery of medications to the eye is challenged by the elimination of drug formulations from the pre-corneal area by tear flow. A Franz diffusion cell was modified to include simulated tear flow to better assess the impact of formulation changes on the diffusion of active moieties across isolated rabbit corneas. To test this model, an in Vitro trans-corneal diffusion study comparing Timoptic (solution) and Timoptic XE (gel) was performed under both static and simulated tear flow conditions. The amount of Timolol that diffused across the cornea as well as the amount of Timolol retained in the pre-corneal (donor) area were compared. In vitro data was compared to published data regarding the total extent (AUC) and rate of diffusion of Timolol in the aqueous humor of rabbits 1. Purpose Results References Conclusion Cross corneal diffusion profiles are an important parameter in predicting ocular drug disposition. The in vitro transcorneal diffusion of Timolol, when using simulated tear flow, compared favorably with the comparative differences of Timoptic® and Timoptic XE  as seen in the in- vivo rabbit pharmacokinetic (PK) profiles The animal PK profiles are, in turn, reflective of the clinical efficacy of Timoptic® and Timoptic XE . A model which implements simulated tear flow appears to be more predictive of Timolol ocular pharmacokinetic profiles and more properly evaluates the impact of formulation changes on the in vivo corneal diffusion profile than a static in vitro corneal diffusion model. Diffusion of Timolol Across Rabbit Cornea under Static Conditions. N = 7 Diffusion of Timolol Across rabbit Cornea with Simulated Tear Flow. N = 7 Rate of Elimination of Timolol from Donor Compartment Rate of Diffusion of Timolol XE and Solution Across Rabbit Cornea Product Donor Cell Condition AUC Relative AUC Timolol Solution Static – No flow 6036 ± Timoptic XE® Static – No flow 5164 ± Timolol Solution Simulated tear flow 1585 ± Timoptic XE® Simulated tear flow 3342 ± Product Donor Cell Condition % Delivered at 180 mins Relative % Delivered at 180 Min Timolol Solution Static – No flow Timoptic XE® Static – No flow Timolol Solution Simulated tear flow Timoptic XE® Simulated tear flow Percent Timolol DeliveredTimolol AUC Introduction Methods Frozen mature rabbit corneas were thawed in DMEM and evaluated for apparent surface damage, swelling and opacityFrozen mature rabbit corneas were thawed in DMEM and evaluated for apparent surface damage, swelling and opacity Rabbit corneas were placed on specially adapted spherical diffusion Franz Cells maintained at 34°Cand dosed with 0.3 mg (about 2 drops) of Timoptic or Timoptic XE.Rabbit corneas were placed on specially adapted spherical diffusion Franz Cells maintained at 34°Cand dosed with 0.3 mg (about 2 drops) of Timoptic or Timoptic XE. For the dynamic experiments the pre corneal layer was initially flushed with PBS at an increased flow rate immediately post-dosage to simulate reflex tear flow then reduced to a basal flow rate for the of the duration of the experiment. Pre-corneal flow was applied for static diffusion experimentsFor the dynamic experiments the pre corneal layer was initially flushed with PBS at an increased flow rate immediately post-dosage to simulate reflex tear flow then reduced to a basal flow rate for the of the duration of the experiment. Pre-corneal flow was applied for static diffusion experiments To evaluate drug retention and extent of absorption characteristics of each Timolol formulation, eroded solution from the pre-corneal layer was collected at intervals for analysis. Receiver chamber solution was also sampled at selected intervals.To evaluate drug retention and extent of absorption characteristics of each Timolol formulation, eroded solution from the pre-corneal layer was collected at intervals for analysis. Receiver chamber solution was also sampled at selected intervals. Analysis of samples were performed via HPLCAnalysis of samples were performed via HPLC Discussion Conclusion Standard static diffusion did not distinguish any differences between Timoptic and Timoptic XE There were significant differences in the characteristics of Timolol solution and Timoptic XE with simulated flow Results Discussion Comparison of the in-vitro Isolated Cornea Models to In vivo data The literature source* indicates that: Relative AUC values of Timolol in the aqueous humor of rabbits are 1.0 for the solution and 2.43 for Timoptic XE ®. Relative C max values are 1.0 for the solution and 1.69 for Timoptic XE ®. t max Values of 30 min are obtained for Timolol solution and 60 min for Timoptic XE ®. In Vitro trans corneal diffusion indicates: Under static conditions: Relative AUC and total % Timolol values were not in agreement with the increased Timoptic XE aqueous humor levels seen from the animal PK data nor were they in the correct rank order. Relative AUC and total Timolol values correctly indicate that a large increase in aqueous humor concentrations should result when Timoptic XE is administered rather than solution 2452